Brentuximab and Refractory Hodgkin's Lymphoma

Brentuximab vedotin, an investigational agent, was associated with complete remission in 34% of patients whose Hodgkin's lymphoma recurred after autologous stem cell transplants, based on data from a phase II trial of 102 patients. For the full story, see https://tinyurl.com/2937bbx